Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(1.03)
# 3,711
Out of 4,896 analysts
48
Total ratings
30.56%
Success rate
-11.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $31.45 | +205.25% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $6.40 | - | 2 | Jun 20, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Overweight | n/a | $50.54 | - | 2 | Jun 10, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $25.00 | - | 2 | Apr 23, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $5.97 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $3.52 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $9.71 | +33.99% | 2 | Mar 13, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $3.15 | - | 2 | Mar 7, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Neutral | n/a | $56.80 | - | 4 | Feb 19, 2025 | |
| INCY Incyte | Reiterates: Neutral | n/a | $68.59 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $39.06 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.93 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $35.02 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $134.21 | +117.57% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $468.85 | -21.08% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.88 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.41 | - | 1 | May 30, 2017 |
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $31.45
Upside: +205.25%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $6.40
Upside: -
Cidara Therapeutics
Jun 10, 2025
Reiterates: Overweight
Price Target: n/a
Current: $50.54
Upside: -
Summit Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $25.00
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.97
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.52
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $9.71
Upside: +33.99%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.15
Upside: -
CRISPR Therapeutics AG
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $56.80
Upside: -
Incyte
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $68.59
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $39.06
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.93
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $35.02
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $134.21
Upside: +117.57%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $468.85
Upside: -21.08%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.88
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.41
Upside: -